← FDA DRUG APPROVALS
FDA ANDA · ANDA203053
EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Sponsor: HETERO LABS LTD V
APPLICATION
ANDA203053
TYPE
ANDA
ORIGINAL APPROVAL
2022-01-24
LATEST ACTION
2022-01-24
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription
Products
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATEPrescription
EFAVIRENZ 600MG, EMTRICITABINE 200MG, TENOFOVIR DISOPROXIL FUMARATE 300MG · TABLET · ORAL
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.